Company: GIFLF
Filing Date: 2025-05-12
Form Type: 6-K
Source: 0001104659-25-047168
Chunk: 23

Company: Grifols SA
Filing Date: 2025-05-12
Form: 6-K
Chunk 23
---
1 2025 Q1 2024 % Var Reported ROW Net Revenues 370,344 368,952 0.4% Variation due to Exchange Rate Effects 1,555 Reported ROW Net Revenues at Constant Currency 371,899 368,952 0.8% In thousands of euros Q1 2025 Q1 2024 % Var Reported Net Revenues 1,785,809 1,625,705 9.8% Variation due to Exchange Rate Effects (39,437) Net Revenues at Constant Currency 1,746,372 1,625,705 7.4% In thousands of euros Q1 2025 Q1 2024 % Var Reported Biopharma Net Revenues 1,521,160 1,394,703 9.1% Variation due to Exchange Rate Effects (33,923) Reported Biopharma Net Revenues at Constant Currency 1,487,237 1,394,703 6.6% In thousands of euros Q1 2025 Q1 2024 % Var Reported Diagnostic Net Revenues 170,043 158,283 7.4% Variation due to Exchange Rate Effects (3,451) Reported Diagnostic Net Revenues at Constant Currency 166,592 158,283 5.2% In thousands of euros Q1 2025 Q1 2024 % Var Reported Bio Supplies Net Revenues 32,557 27,013 20.5% Variation due to Exchange Rate Effects (1,243) Reported Bio Supplies Net Revenues at Constant Currency 31,314 27,013 15.9% In thousands of euros Q1 2025 Q1 2024 % Var Reported Others & Intersegments Net Revenues 62,050 45,707 35.8% Variation due to Exchange Rate Effects (820) Reported Other & Intersegments Net Revenues at Constant Currency 61,230 45,707 34.0% Business Performance Financials Final Remarks Annex

- 32 - Q1 2025 Results EBITDA Adjusted Reconciliation at cc | Q1 2025 Business Performance Financials Final Remarks Annex EBITDA Adjusted Q1'25: In thousands of euros Q1 2025 Q1 2024 % Var Reported EBITDA Adjusted 400 350 14.3% Variation due to Exchange Rate Effects (0) EBITDA Adjusted at Constant Currency